Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Response of Levalbuterol vs Racemic Albuterol in Asthma
NCT00685425Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Oct 2002
- Primary completion
- Mar 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of levalbuterol in Exercise-induced bronchoconstriction (EIB) (2 arms), sponsored by Sumitomo Pharma America. Primary endpoint: FEV1 AUC 0-60 (% decrease from post-dose/pre-challenge FEV1). Started Oct 2002; status: completed.
02
Drugs
levalbuterol
03
Conditions
Exercise-induced bronchoconstriction (EIB)
Beyond the preview
Go deeper on NCT00685425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00685425.